BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the ...
NOTE. P < .00357 represents statistical significance after the Bonferroni correction. Abbreviations: MAPK, mitogen-activated protein kinase; NA, unable to be calculated; NR, not reached; OS, overall ...
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...
Erasca, Inc. presents promising preclinical data on ERAS-0015 and ERAS-4001 targeting RAS/MAPK pathway cancers at AACR meeting. Erasca, Inc. presented new preclinical data at the American Association ...
BUFFALO, NY – August 13, 2025 – A new research paper was published in Volume 16 of Oncotarget on July 29, 2025, titled “PCAIs stimulate MAPK, PI3K/AKT pathways and ROS-Mediated apoptosis in aromatase ...
Worldwide rights position Erasca to advance ERAS-0015 through a unified global development strategy. ERAS-0015’s promising early clinical data underscore its potential to be a b ...
Explore the latest colorectal cancer treatment advances, from precision oncology and immunotherapy to ADCs, bispecifics, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results